Encorafenib
- Generic Name
- Encorafenib
- Brand Names
- Braftovi
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27ClFN7O4S
- CAS Number
- 1269440-17-6
- Unique Ingredient Identifier
- 8L7891MRB6
- Background
Encorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most fr...
- Indication
Encorafenib is indicated in combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation and metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. It is also indicated in combination with cetuximab for the treatment of adult patients with metastatic colorecta...
- Associated Conditions
- Metastatic Colorectal Cancer (CRC), Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Unresectable Melanoma
- Associated Therapies
- -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 210
- Registration Number
- NCT02857270
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)
- Conditions
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- University of Heidelberg Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT02834364
- Locations
- 🇩🇪
Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany
🇩🇪Universitätsklinikum Tübingen, Medizinische Klinik II, Tübingen, Germany
🇩🇪Mediz. Klinik und Poliklinik 1, Universitätsklinikum Dresden, Dresden, Germany
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
- Conditions
- Interventions
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Curegenix Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT02675946
- Locations
- 🇺🇸
Edward H. Kaplan MD and Associates, Skokie, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Care, Long Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.